Drug Developer GNQ To Go Public Via $500M SPAC Deal
By Jade Martinez-Pogue · March 17, 2026, 3:10 PM EDT
Techbio company GNQ Insilico has announced plans to go public by merging with special-purpose acquisition company IB Acquisition Corp. in a deal that values it at $500 million and was built...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login